Want to see PYXS full AI Analyst Report?
PYXS Stock Chart & Stats
$3.06
$0.30(11.49%)
At close: 4:00 PM EDT
$3.06
$0.30(11.49%)
Day’s Range― - ―
52-Week Range$1.03 - $5.55
Previous CloseN/A
Volume197.33K
Average Volume (3M)1.33M
Market Cap
$312.78M
Enterprise Value$175.98
Total Cash (Recent Filing)$33.00M
Total Debt (Recent Filing)$17.83M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 17, 2026EPS Estimate
-0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding83,408,050
10 Day Avg. Volume599,728
30 Day Avg. Volume1,327,746
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)1.34
Price to Sales (P/S)5.16
P/FCF Ratio-1.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.14Price Target Upside133.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.22
Revenue Forecast (FY)$57.14K
Bulls Say, Bears Say
Bulls Say
Extended Cash RunwayThe ~$50M upfront financing, with up to ~$64M from warrants, is intended to extend runway into Q2 2027. That reduces near-term funding risk and gives management time to generate clinical evidence before another major financing decision.
Clinical Pipeline DevelopmentMICVO remains the company’s central development asset, with funding directed to follow-up and expansion-trial analyses plus planned combination data. This creates identifiable clinical catalysts and preserves potential product value, although efficacy is not yet established.
Governance ContinuityApproval of three directors through 2029 and Ernst & Young as independent auditor supports board continuity and reporting oversight. Stable governance can help maintain execution discipline and financial controls while the company advances its capital-intensive clinical program.
Bears Say
Declining, Non-Recurring RevenueTTM revenue is only $11.0M and declined about 20%; the pack says revenue is driven by sporadic, non-recurring licensing or milestone events rather than steady product or royalty income. This limits visibility and leaves commercialization unproven.
Heavy Operating Cash BurnOperating and free cash flow of approximately -$67.9M show that the business remains far from self-funding. Continued clinical spending without recurring product revenue will require additional capital over time, creating financing dependence and potential execution constraints.
Weakening Balance SheetDebt is approximately 1.6 times equity and assets have contracted materially alongside ongoing losses. The smaller equity cushion reduces financial flexibility, increases dependence on external financing, and leaves shareholders more exposed to future dilution or funding pressure.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $1.03 and its highest was $5.55 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $312.78M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Nov 17, 2026 which is in 74 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Aug 13, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.35 by -$0.05.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.28.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 83,408,050 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.35. Following the earnings report the stock price went down -5.346%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.14 (133.43% Upside)
$7.14 (133.43% Upside)
Hedge Fund Trend
Increased
By 524.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
142.51%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-55.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Pyxis Oncology
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$7.14
▲(133.43% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
2.14% Insiders
3.08% Mutual Funds
32.10% Other Institutional Investors
59.03% Public Companies and Individual Investors